Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 13/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.40 |
| ▸ | ATR | Q13535 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23214098 | 0.81 | ALDH1A1 (0.40) | LCK | |
| SCHEMBL1563222 | 0.81 | LCK (0.48) | LCKCA1CA2PI4KB | |
| SCHEMBL23214462 | 0.78 | LCK (0.46) | LCKCA1CA2PI4KBATR | |
| SCHEMBL17298800 | 0.77 | CA1 (0.43) | LCKCA1CA2PI4KB | |
| SCHEMBL13403561 | 0.77 | LCK (0.46) | LCKCA1CA2PI4KB | |
| SCHEMBL22667919 | 0.76 | LCK (0.45) | LCKCA1CA2PI4KBATR | |
| SCHEMBL13437781 | 0.76 | LCK (0.45) | LCKCA1CA2PI4KB | |
| SCHEMBL29556655 | 0.76 | GCK (0.52) | LCKCA1CA2PI4KB | |
| SCHEMBL10428936 | 0.75 | LCK (0.44) | LCKCA1CA2PI4KB | |
| SCHEMBL8625658 | 0.75 | LCK (0.44) | LCKCA1CA2PI4KB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114630822-B | Biaryl dihydroorotate acid dehydrogenase inhibitors | 詹森生物科技公司 | 2024-10-01 | — | — | CN | disclosed |
| US-20240158414-A1 | BI-ARYL DIHYDROOROTATE DEHYDROGENASE INHIBITORS | JANSSEN BIOTECH, INC. | 2024-05-16 | — | — | US | disclosed |
| EP-4041714-B1 | BI-ARYL DIHYDROOROTATE DEHYDROGENASE INHIBITORS | JANSSEN BIOTECH INC (US) | 2023-12-13 | — | — | EP | disclosed |
| EP-4041714-A1 | BI-ARYL DIHYDROOROTATE DEHYDROGENASE INHIBITORS | Janssen Biotech, Inc. (US) | 2022-08-17 | — | — | EP | disclosed |
| CN-114630822-A | Biaryl dihydroorotate dehydrogenase inhibitors | 詹森生物科技公司 | 2022-06-14 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240158414-A1 | BI-ARYL DIHYDROOROTATE DEHYDROGENASE INHIBITORS | DHODH, DLD, DPYD | LCK 3925/4885CA1 3902/4885CA2 1792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.